Publications by authors named "Abidemi K Adeniji"
Article Synopsis
- The CLARITY and CLARITY Extension studies showed that cladribine tablets (CT) significantly improve clinical outcomes in patients with relapsing-remitting multiple sclerosis (RRMS) compared to placebo.
- In the CLARITY Extension, patients who previously received placebo had more T1 gadolinium-enhanced lesions initially, but those treated with CT showed a 90.4% reduction in such lesions over time.
- Most patients maintained their improvements without new lesions, but some who switched from CT to placebo during the extension exhibited increased MRI activity, particularly if there was a long gap between treatments.
The product limit or Kaplan-Meier (KM) estimator is commonly used to estimate the survival function in the presence of incomplete time to event. Application of this method assumes inherently that the occurrence of an event is known with certainty. However, the clinical diagnosis of an event is often subject to misclassification due to assay error or adjudication error, by which the event is assessed with some uncertainty.
View Article and Find Full Text PDFArticle Synopsis
- - In the 2-year CLARITY study, cladribine tablets showed significant improvements in both clinical outcomes and MRI results for patients with relapsing-remitting multiple sclerosis compared to those on placebo.
- - The 2-year Extension study involved re-randomizing participants, with those originally on placebo receiving cladribine, while previous cladribine users were split between continuing treatment and placebo—all participants remained unaware of their assigned treatment.
- - Results indicated that cladribine led to durable clinical benefits, with around 75% of patients remaining relapse-free even after transitioning to placebo for two years, while severe side effects like Grade 3 lymphopenia occurred more frequently with cladribine but were manageable.*